This year can be regarded as a momentous period for RMTI's business because this is the first time in its history that it has achieved steady revenue growth.
Rockwell Medical (RMTI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Rockwell Medical (RMTI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
RMTI continues to outperform its peers, banking on its focus on optimizing business to drive sustainable profitability and meaningful cash flow generation.
Rockwell develop concentrates for hemodialysis, which is a process that seeks to artificially replace kidney function in patients with chronic failure. Despite being a critical product, there's currently no large competitor dominating the category and the company is a leader. After years of constant CEO turnover and poor results, Mr. Mark Strobeck has turned around and has already reached its first profitable quarter ever.
Does Rockwell Medical (RMTI) have what it takes to be a top stock pick for momentum investors? Let's find out.
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Rockwell Medical (RMTI) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Rockwell Medical (RMTI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Rockwell Medical (RMTI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Rockwell Medical (RMTI) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Rockwell Medical, Inc. (RMTI) Q2 2024 Earnings Call Transcript
Rockwell Medical (RMTI) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.18 per share a year ago.